Description

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comprehensive multi-cancer tests with companion diagnostic claims received approval in late 2020. Driven by multiple FDA liquid biopsy approvals in 2021, the ability to diagnose a tumor and monitor its progression and treatment response without performing a tissue biopsy is one of the most groundbreaking advancements in the In vitro diagnostics (IVD) market. In a field of more than 35 US industry participants, Frost & Sullivan independently plotted the top 9 Liquid Biopsy companies in this Frost Radar™ analysis: GRAIL, Exact Sciences Corp., Roche Foundation Medicine, Guardant Health, Natera, Inc., Helio Genomics (formerly Helio Health, Helio), Freenome, Quanterix, and Tempus, Inc., that are truly innovating and best positioned to deliver high value to customers in the future.

Author: Amartya Bose